Luteinizing Hormone Releasing Hormone-Targeted Cisplatin-Loaded Magnetite Nanoclusters for Simultaneous MR Imaging and Chemotherapy of Ovarian Cancer
| Autor: | Tatiana K. Bronich, Alexander V. Kabanov, Richey M. Davis, Zhengyuan Zhou, Xinming M. Liu, Marina Sokolsky-Papkov, Youn Gee Seo, Hemant M. Vishwasrao, Judy S. Riffle, Alyssa M. Master, Nikorn Pothayee, Michael D. Boska, Dongfen Yuan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cisplatin
General Chemical Engineering Nanotechnology 02 engineering and technology General Chemistry 010402 general chemistry 021001 nanoscience & nanotechnology medicine.disease 01 natural sciences Article 0104 chemical sciences Nanoclusters chemistry.chemical_compound chemistry Cancer cell Materials Chemistry medicine Cancer research 0210 nano-technology Receptor Luteinizing hormone Ovarian cancer Ethylene glycol medicine.drug Hormone |
| Zdroj: | Chem Mater |
| ISSN: | 1520-5002 0897-4756 |
| Popis: | Given the superior soft tissue contrasts obtained by MRI and the long residence times of magnetic nanoparticles (MNPs) in soft tissues, MNP-based theranostic systems are being developed for simultaneous imaging and treatment. However, development of such theranostic nanoformulations presents significant challenges of balancing the therapeutic and diagnostic functionalities in order to achieve optimum effect from both. Here we developed a simple theranostic nanoformulation based on magnetic nanoclusters (MNCs) stabilized by a bisphosphonate-modified poly(glutamic acid)-b-(ethylene glycol) block copolymer and complexed with cisplatin. The MNCs were decorated with luteinizing hormone releasing hormone (LHRH) to target LHRH receptors (LHRHr) overexpressed in ovarian cancer cells. The targeted MNCs significantly improved the uptake of the drug in cancer cells and decreased its IC(50) compared to the nontargeted formulations. Also, the enhanced LHRHr-mediated uptake of the targeted MNCs resulted in enhancement in the T(2)-weighted negative contrast in cellular phantom gels. Taken together, the LHRH-conjugated MNCs show good potential as ovarian cancer theranostics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|